Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Clin Cancer Res. 2013 Dec 15;19(24):10.1158/1078-0432.CCR-13-1746. doi: 10.1158/1078-0432.CCR-13-1746

Figure 3. 52 melanomas genotyped on the FoundationOne™ assay.

Figure 3

Schematic of the mutation distribution in 52 patient melanomas genotyped by the FoundationOne™ assay. Each column of boxes indicates a single patient, where green boxes indicate the presence of a mutation in BRAF, NRAS, KIT, GNAQ, and/or GNA11 and grey boxes indicate lack of mutation(s). Cases with V600E/K BRAF mutations, non-V600 BRAF mutations, BRAF fusions and certain NRAS mutations are indicated. Specific mutations for each case can be found in Supplementary Table S1. No KIT mutations were identified. Note the difference in the percent of cases positive for BRAF V600 mutations in this cohort versus those genotyped in Figure 4, demonstrating that this cohort was enriched for cases lacking BRAF V600 alterations.